Scientific Online Resource System

Scripta Scientifica Medica

THERAPEUTIC EFFECT OF MILGAMMA N IN SYMPTOMATIC NEURALGIA IN THE COURSE AND AFTER HERPES ZOSTER GANGLIONITIS

P. Drumeva, S. Pavlov, N. Deleva

Abstract

Herpes zoster is a dermatovirosis that occurs at different age. However, with the patients aged over 60 years it presents with a painful syndrome preceded, accompanied or lasting up to one year after fading away of the eruptions. Intake of B-group vitamins favourably influences on the restoration of sensory nerves being mainly affected and causing the protracted painful syndrome. Milgamma N preparation in the shape of capsules is a combination of 40mg of vit. Bi, of 90mg of vit. Вб, and of 250 у of vit. Bn and ensures an optimal intestinal resorption. The authors followed-up dynamically the therapeutic effect of Milgamma N in capsules on the development of skin lesions and painful syndrome in 15 patients (7 males and 8 females) with herpes zoster. The duration of the therapy was 4 weeks long. The following protocol was made use of: week one - two capsules three times daily and weeks two through four - three times one capsule daily. The dermatologic and neurologic status as well as the subjective evaluation of the therapeutic effect was monitored in all the patients. There was a complete or an almost complete remission in 13 patients (86,7% of the cases) after one-month treatment. The skin lesions underwent an involution during a period of 10-17 days. The one-month schedule for treatment of herpes zoster with Milgamma N proved to be effective in a moderate degree of a painful syndrome and most common localization of the eruptions.


Keywords

herpes zoster; Milgamma N; ganglionitis; pain evaluation; therapeutic protocol

Full Text


References

Christiansen, N., R. Haake, D. D. Hurd. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing bone marrow transplant.- Bone Marrow Tranplant., 7, 1991, No 6, 435-437.

Cook, M., J . G. Stevens. Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intraaxonal transport of infection.- Infect. Immun., 7, 1973, No 2, 272-288.

Greb, A., R. Bitsch. Comparative bioavailability of various thiamine derivatives after oral administration.- Int. J. Clin. Pharmacol. Ther., 36, 1998, No 4, 216-221.

Hope-Simpson, R. The nature of herpes zoster: a long term study and a new hypothesis.- Proc. Roy. Soc. Med., 58, 1965,9-20.

Mahalingam, R., M. Wellish, W. Wolf, A. N. Dueland, R. Cohrs, A. Vafei, D. Gilden. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia.- New Engl. J. Med., 323, 1990, No 10,627-631.

Nakano, T., E. Awaki, S. Araga, H. Takai, K. Inoue, K. Takahashi. Recurrent herpes zoster myelitis treated with human interferon alpha: a case report.- Acta Neurol. Scand., 85, 1992, No 5, 372-375.

Poscher, M. Successful treatment of varicella zoster meningoencephalitis in patients with AIDS: report of four cases and review.- AIDS, 8, 1994, No 8, 1115-1117.

Schimpff, S., A. Serpick, B. Stoller, B. Rumack, H. Mellin, J . M. Joseph, J . Block. Varicella-Zoster infection in patients with cancer.- Ann. Intern. Med.. 76, 1972, No 2, 241-254.

Stracke, H., A. Lindemann, K.. Federlin.A benfotiamin-vitamin B combination in treatment of diabetic polyneuropathy.- Exp. Clin. Endocrinol. Diabet., 104, 1996, No 4, 311-316.




DOI: http://dx.doi.org/10.14748/ssm.v34i0.2795

Refbacks

Article Tools
Email this article (Login required)
About The Authors

P. Drumeva

S. Pavlov

N. Deleva

Font Size


|